BGI Group has developed beyond the phase of participating and excelling, achieving comprehensive leadership in certain areas of life sciences by focusing on the forefront of basic research and key challenges. The group strives to realize significant technological breakthroughs and to develop cutting-edge technologies. In 2023, the DCS Lab Global Scientific Research Empowerment Program was officially launched. Laboratories have been established or are slated for establishment in Chinese cities such as Hangzhou, as well as in international cities including Brisbane, Australia.

In 2023, BGI launched a series of cutting-edge products, such as the Spatiotemporal Cloud Platform, mIF+ Transcriptome, and H&E+ Transcriptome, which have significantly reduced the costs of undertaking high-resolution spatiotemporal research on a single sample. These innovations have created a comprehensive spatiotemporal ecosystem that empowers scientific research across various fields. Currently, BGI's STOmics technology is assisting numerous universities and research institutions around the world to conduct research in diverse areas, including organ regeneration, embryonic development, brain science, cancer, and more.

BGI has upheld its leading position in the 2023 Nature Index ranking as the foremost corporate institution for biological sciences research in the Asia Pacific region for the eighth consecutive year. Additionally, four distinguished BGI researchers have been included in Clarivate Analytics' Highly Cited Researchers list for 2023, the ninth consecutive year for BGI.

In 2023, BGI achieved multiple breakthroughs in research fields such as brain science, disease, zoology, botany, evolution, and development. This year, BGI has published a total of 382 papers, including 62 articles in CNNS journals (Nature and its subsidiary journals, Science and its subsidiary journals, Cell and its subsidiary journals, and the New England Journal of Medicine ).

To date, BGI has published a total of 4,892 papers, including 569 articles in CNNS journals, 15 articles in the main journal.

BGI Group has developed a diverse array of detection products that cover reproductive health, cancer, infectious disease prevention, and chronic disease management, addressing health needs throughout the entire life cycle. These products have benefited over 30 million people to date. In the field of gene therapy, Hemogen, a subsidiary of BGI Group, has shown notable clinical success. So far, five patients with β-thalassemia and one patient with α-thalassemia have become free from the need for blood transfusions after undergoing treatment.

In 2023, government departments or institutional organizations from nearly 40 countries, including Saudi Arabia, Hungary, Serbia, and Indonesia, conducted mutual visits with BGI Group to exchange ideas on platform construction, the medical industry development, and talent training.

In 2023, BGI Group conducted mutual visits with government departments or institutions from dozens of countries.

In August, Professor Rajeev Varshney, a Fellow of the Royal Society, Director of the Centre for Crop and Food Innovation, Director of the Western Australian State Biotechnology Centre, and International Chair in Agriculture and Food Security at Murdoch University, Australia, commented on the collaboration with BGI, noting: “One key thing with BGI Group is that they are not just a service provider. When they work with a scientist or research institute, they work as true collaborators in terms of their data analysis, in terms of their interpretation.”

To date, BGI has been involved in proposing or contributing to 311 global standards. These standards encompass areas such as accurate diagnosis and treatment of tumors, life sciences research tools, agricultural practices, and others. BGI has received over 140 international quality system certifications and accreditations, covering aspects like laboratory operations, environmental management, occupational health, information security, and personal privacy.